Our advocacy promotes transparency, accountability and the public interest in the field of pharmaceuticals. Our evidence-based advocacy aims to guarantee better and affordable medicines for Europe by questioning and reforming the current pharmaceutical business model and calling for better access to medicines for all.
A series of online, live, public dialogues putting the spotlight on actionable solutions on access to medicines for decision-makers in Europe.
The revision of the EU pharmaceutical legislation: an opportunity to adopt a bold patient-centred set of rules.
The revision of the EU pharmaceutical legislation: balancing between innovation incentives and access to affordable medicines
Public consultation response highlighting critical aspects for the forthcoming revision of the pharmaceutical legislation.
Speech given by EPHA’s Director General Dr. Milka Sokolović on better access to medicines within the Oslo Medicines Initiative.
Analysis & Opinion
The ever-increasing prices of cancer medicines across Europe causes severe threats to patient access and health systems.
South Africa and India submitted a proposal to waiver certain dispositions of the Trade- Related aspects of Intellectual Property (TRIPS)
In the EU there are significant disparities in accessing medicines thus leading to health inequalities across the Union.